search
Back to results

A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1)

Primary Purpose

Healthy Volunteers, Haemophilia A With or Without Inhibitors

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
NNC0365-3769 (Mim8)
Placebo (Mim8)
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Volunteers

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

Single ascending dose part 1:

  • Male, aged 18-45 years (both inclusive) at the time of signing informed consent
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator

Multiple ascending dose part 2:

  • Male, aged 12-64 years (both inclusive) at the time of signing informed consent (Germany and Japan have local requirements)
  • Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical records

Exploratory biomarker cohort:

  • Male, aged equal to or above 12 years at the time of signing informed consent (Germany and Japan have local requirements)
  • Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical recordsv

Exclusion Criteria:

Part 1:

  • Factor VIII activity equal to or above 150% at screening
  • Increased risk of thrombosis, e.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease

Part 2:

  • Known congenital or acquired coagulation disorders other than haemophilia A
  • Increased risk of thrombosis as evaluated by the investigator. E.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Advanced atherosclerotic disease (e.g. known history of ischemic heart disease, ischemic stroke) as evaluated by the investigator
  • Any autoimmune disease that may increase the risk of thrombosis
  • Receipt of emicizumab or drugs with similar modes of action within 5 half-lives before trial product administration
  • Ongoing or planned immune tolerance induction therapy

Exploratory biomarker cohort:

  • Known congenital or acquired coagulation disorders other than haemophilia A
  • Increased risk of thrombosis as evaluated by the investigator. E.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Advanced atherosclerotic disease (e.g. known history of ischemic heart disease, ischemic stroke) as evaluated by the investigator
  • Any autoimmune disease that may increase the risk of thrombosis
  • Ongoing or planned immune tolerance induction therapy

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Placebo Comparator

Experimental

Arm Label

Single dose (part 1) Mim8

Single dose (part 1) placebo

Multiple dose (part 2)

Arm Description

Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.

Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.

Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.

Outcomes

Primary Outcome Measures

Part 1: Number of treatment emergent adverse events
Count
Part 2: Number of treatment emergent adverse events
Count
Part 2, extension: Number of treatment emergent adverse events
Count

Secondary Outcome Measures

Part 1: Number of injection site reactions
Count
Part 1: Relative change in D-dimer
Percent
Part 1: Relative change in prothrombin fragment 1 and 2
Percent
Part 1: Relative change in fibrinogen
Percent
Part 1: Relative change in platelets
Percent
Part 1: Cmax, SD: the maximum concentration of Mim8 after a single dose
μg/mL
Part 1: AUC0-inf, SD: the area under the Mim8 concentration-time curve from time 0 to infinity after a single dose
μg*day/mL
Part 1: t1/2, SD: the terminal half-life of Mim8 after a single dose
Days
Part 1: tmax, SD: the time to maximum concentration of Mim8 after a single dose
Days
Part 1: Change in activated partial thromboplastin time
Seconds
Part 2 (weekly and monthly dosing): Number of injection site reactions
Count
Part 2 (weekly and monthly dosing): Occurrence of anti-Mim8 antibodies
Count
Part 2 (weekly and monthly dosing): Relative change in D-dimer
Percent
Part 2 (weekly and monthly dosing): Relative change in prothrombin fragment 1 and 2
Percent
Part 2 (weekly and monthly dosing): Relative change in fibrinogen
Percent
Part 2 (weekly and monthly dosing): Relative change in platelets
Percent
Part 2 PK session 2 (weekly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses
μg/mL
Part 2 PK session 2 (weekly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses
μg*day/mL
Part 2 PK session 2 (monthly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses
μg/mL
Part 2 PK session 2 (monthly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses
μg*day/mL
Part 2 (weekly dosing): Mean of maximum thrombin generation (peak height)
nM
Part 2 (monthly dosing): Mean of maximum thrombin generation (peak height)
nM
Part 2, extension: Number of injection site reactions
Count
Part 2, extension: Occurrence of anti-Mim8 antibodies
Count

Full Information

First Posted
December 17, 2019
Last Updated
September 26, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04204408
Brief Title
A Research Study Investigating Mim8 in People With Haemophilia A
Acronym
FRONTIER1
Official Title
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Doses of NNC0365-3769 (Mim8) in Healthy Subjects and in Subjects With Haemophilia A With or Without Factor VIII Inhibitors
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 10, 2020 (Actual)
Primary Completion Date
February 24, 2025 (Anticipated)
Study Completion Date
February 24, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected with a thin needle in the skin of the stomach, using a pen-injector. The study will last for up to 44 months. It consists of a main phase (part 1 and part 2) and an extension phase. In part 1, participants will be injected only once with either Mim8 or a "dummy" medicine (placebo) - which one will be decided by chance. In part 2 and the extension phase participants will get an Mim8 injection weekly or monthly.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Volunteers, Haemophilia A With or Without Inhibitors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Part 1 placebo-controlled double-blind within cohorts (phase 1) Part 2 open-label (phase 2)
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Sponsor staff involved in the clinical trial is masked according to company standard procedures
Allocation
Randomized
Enrollment
275 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single dose (part 1) Mim8
Arm Type
Experimental
Arm Description
Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.
Arm Title
Single dose (part 1) placebo
Arm Type
Placebo Comparator
Arm Description
Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.
Arm Title
Multiple dose (part 2)
Arm Type
Experimental
Arm Description
Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.
Intervention Type
Drug
Intervention Name(s)
NNC0365-3769 (Mim8)
Intervention Description
Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
Intervention Type
Drug
Intervention Name(s)
Placebo (Mim8)
Intervention Description
Mim8 placebo administered subcutaneously (s.c., under the skin)
Primary Outcome Measure Information:
Title
Part 1: Number of treatment emergent adverse events
Description
Count
Time Frame
From time of dosing (Day 1) to Week 16
Title
Part 2: Number of treatment emergent adverse events
Description
Count
Time Frame
From time of first dosing (Day 1) to Week 12
Title
Part 2, extension: Number of treatment emergent adverse events
Description
Count
Time Frame
From Week 12 up to Week 176 (16 weeks after last dose)
Secondary Outcome Measure Information:
Title
Part 1: Number of injection site reactions
Description
Count
Time Frame
From time of dosing (Day 1) to Week 16
Title
Part 1: Relative change in D-dimer
Description
Percent
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: Relative change in prothrombin fragment 1 and 2
Description
Percent
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: Relative change in fibrinogen
Description
Percent
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: Relative change in platelets
Description
Percent
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: Cmax, SD: the maximum concentration of Mim8 after a single dose
Description
μg/mL
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: AUC0-inf, SD: the area under the Mim8 concentration-time curve from time 0 to infinity after a single dose
Description
μg*day/mL
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: t1/2, SD: the terminal half-life of Mim8 after a single dose
Description
Days
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: tmax, SD: the time to maximum concentration of Mim8 after a single dose
Description
Days
Time Frame
From baseline (Day 1) to Week 16
Title
Part 1: Change in activated partial thromboplastin time
Description
Seconds
Time Frame
From baseline (Day 1) to Week 16
Title
Part 2 (weekly and monthly dosing): Number of injection site reactions
Description
Count
Time Frame
From time of first dosing (Day 1) to Week 12
Title
Part 2 (weekly and monthly dosing): Occurrence of anti-Mim8 antibodies
Description
Count
Time Frame
From baseline (Day 1) to Week 12
Title
Part 2 (weekly and monthly dosing): Relative change in D-dimer
Description
Percent
Time Frame
From baseline (Day 1) to Week 12
Title
Part 2 (weekly and monthly dosing): Relative change in prothrombin fragment 1 and 2
Description
Percent
Time Frame
From baseline (Day 1) to Week 12
Title
Part 2 (weekly and monthly dosing): Relative change in fibrinogen
Description
Percent
Time Frame
From baseline (Day 1) to Week 12
Title
Part 2 (weekly and monthly dosing): Relative change in platelets
Description
Percent
Time Frame
From baseline (Day 1) to Week 12
Title
Part 2 PK session 2 (weekly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses
Description
μg/mL
Time Frame
From Day 57 to Day 64
Title
Part 2 PK session 2 (weekly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses
Description
μg*day/mL
Time Frame
From Day 57 to Day 64
Title
Part 2 PK session 2 (monthly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses
Description
μg/mL
Time Frame
From Day 57 to Day 85
Title
Part 2 PK session 2 (monthly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses
Description
μg*day/mL
Time Frame
From Day 57 to Day 85
Title
Part 2 (weekly dosing): Mean of maximum thrombin generation (peak height)
Description
nM
Time Frame
From Day 57 to Day 64
Title
Part 2 (monthly dosing): Mean of maximum thrombin generation (peak height)
Description
nM
Time Frame
From Day 57 to Day 85
Title
Part 2, extension: Number of injection site reactions
Description
Count
Time Frame
From Week 12 up to Week 176 (16 weeks after last dose)
Title
Part 2, extension: Occurrence of anti-Mim8 antibodies
Description
Count
Time Frame
From Week 12 up to Week 176 (16 weeks after last dose)

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Single ascending dose part 1: Male, aged 18-45 years (both inclusive) at the time of signing informed consent Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator Multiple ascending dose part 2: Male, aged 12-64 years (both inclusive) at the time of signing informed consent (Germany and Japan have local requirements) Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical records Exploratory biomarker cohort: Male, aged equal to or above 12 years at the time of signing informed consent (Germany and Japan have local requirements) Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical recordsv Exclusion Criteria: Part 1: Factor VIII activity equal to or above 150% at screening Increased risk of thrombosis, e.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis Any clinical signs or established diagnosis of venous or arterial thromboembolic disease Part 2: Known congenital or acquired coagulation disorders other than haemophilia A Increased risk of thrombosis as evaluated by the investigator. E.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing Any clinical signs or established diagnosis of venous or arterial thromboembolic disease with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing Advanced atherosclerotic disease (e.g. known history of ischemic heart disease, ischemic stroke) as evaluated by the investigator Any autoimmune disease that may increase the risk of thrombosis Receipt of emicizumab or drugs with similar modes of action within 5 half-lives before trial product administration Ongoing or planned immune tolerance induction therapy Exploratory biomarker cohort: Known congenital or acquired coagulation disorders other than haemophilia A Increased risk of thrombosis as evaluated by the investigator. E.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing Any clinical signs or established diagnosis of venous or arterial thromboembolic disease with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing Advanced atherosclerotic disease (e.g. known history of ischemic heart disease, ischemic stroke) as evaluated by the investigator Any autoimmune disease that may increase the risk of thrombosis Ongoing or planned immune tolerance induction therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Reporting Anchor and Disclosure (1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45404
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Innsbruck
ZIP/Postal Code
A 6020
Country
Austria
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1527
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Facility Name
Novo Nordisk Investigational Site
City
Milano
State/Province
MI
ZIP/Postal Code
20124
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Roma
ZIP/Postal Code
00161
Country
Italy
Facility Name
Novo Nordisk Investigational Site
City
Aichi
ZIP/Postal Code
466-8560
Country
Japan
Facility Name
Novo Nordisk Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-776
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Poznań
State/Province
Wielkopolskie
ZIP/Postal Code
60-569
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Parktown, Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2193
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Novo Nordisk Investigational Site
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Facility Name
Novo Nordisk Investigational Site
City
Ankara
ZIP/Postal Code
06230
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Edirne
ZIP/Postal Code
22030
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
Izmir
ZIP/Postal Code
35100
Country
Turkey
Facility Name
Novo Nordisk Investigational Site
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Research Study Investigating Mim8 in People With Haemophilia A

We'll reach out to this number within 24 hrs